Previous close | 0.0241 |
Open | 0.0241 |
Bid | 0.0163 x 0 |
Ask | 0.0361 x 0 |
Day's range | 0.0241 - 0.0241 |
52-week range | 0.0170 - 0.0800 |
Volume | |
Avg. volume | 475 |
Market cap | 2.169M |
Beta (5Y monthly) | -1.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0600 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
TORONTO, June 27, 2024--Jack Nathan Medical Corp. (TSXV: "JNH"; OTCQB: "JNHMF") (the "Company") is pleased to announce that all of the matters presented for approval at its annual and special meeting of shareholders of the Company (the "AGM") held on Thursday, June 27, 2024 were approved.
TORONTO, June 20, 2024--Jack Nathan Medical Corp. (TSXV: JNH, OTCQB: JNHMF) ("Jack Nathan Health", "JNH" or the "Company") announced today its unaudited interim consolidated financial results for the first quarter of fiscal 2025, three months ended April 30, 2024. Jack Nathan Health’s financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").
Jack Nathan Medical ( CVE:JNH ) Full Year 2024 Results Key Financial Results Revenue: CA$19.1m (up 24% from FY 2023...